PRESSRELEASES
10 November, 2021
Nanexa publishes interim report for January – September 2021
Substantial orders and pause in the NEX-18 study
25 October, 2021
Nanexa initiates complementary preclinical studies
Nanexa AB today announces that the company has initiated complementary preclinical studies to investigate what caused the moderate skin reactions that occurred in the company’s phase I study with NEX-18, a depot formulation of 5-azacitidine.
CURRENT
11 november, 2021
Redeye Life Science Day, VD David Westberg presenterar
10 november, 2021
Webcast och frågestund med VD David Westberg och styrelseledamot Bengt Gustavsson
NEWSLETTER
